Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Clearmind Medicine Inc. Common Shares

Healthcare US CMND

3.98USD
1.07(36.77%)

Last update at 2026-06-05T20:28:00Z

Day Range

3.264.55
LowHigh

52 Week Range

0.5952.40
LowHigh

Fundamentals

  • Previous Close 2.91
  • Market Cap2.73M
  • Volume41708884
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.81996M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-24.12

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-12-31 2022-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-12-31 2022-10-31
Income before tax -3.78619M -6.78838M -11.82804M -9.37005M -9.88552M
Minority interest - - - - -
Net income -3.85663M -7.31451M -11.85193M -9.41081M -9.92852M
Selling general administrative 3.57M 3.26M 6.60M 5.43M 5.43M
Selling and marketing expenses - 1.09M 0.18M - -
Gross profit -0.04936M -0.07109M -0.07906M - -0.11962M
Reconciled depreciation 0.05M 0.05M 0.06M 0.11M 0.11M
Ebit -3.76665M -6.73805M -11.82804M -8.53258M -9.86477M
Ebitda -3.71729M -6.66696M -11.74898M -8.41920M -9.74515M
Depreciation and amortization 0.05M 0.07M 0.08M 0.11M 0.12M
Non operating income net other - - - - -
Operating income -5.66665M -7.99694M -8.66596M -8.53258M -9.00198M
Other operating expenses 5.67M 8.00M 8.67M 8.53M 9.00M
Interest expense 0.02M 0.05M 0.01M 0.02M 0.02M
Tax provision 0.07M 0.38M 0.02M 0.04M 0.04M
Interest income 0.13M 0.27M 0.07M - 0.00000M
Net interest income 0.11M 0.24M 0.06M -0.01968M -0.01968M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.07M 0.53M 0.02M 0.04M 0.04M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 5.62M 7.93M 8.59M 8.53M 8.88M
Cost of revenue 0.05M 0.07M 0.08M - 0.12M
Total other income expense net 1.88M 1.21M -3.16208M -0.83747M -0.88354M
Discontinued operations - - - - -
Net income from continuing ops -3.85698M -5.25468M -8.62084M -9.41081M -9.41081M
Net income applicable to common shares - - - -9.41081M -9.41081M
Preferred stock and other adjustments - - - - -
Breakdown 2025-10-31 2024-10-31 2023-12-31 2023-10-31 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-12-31 2023-10-31 2022-12-31
Total assets 6.08M 10.10M 5.95M 5.95M 1.13M
Intangible assets 0.10M 0.15M - 0.16M 0.18M
Earning assets - - - - -
Other current assets 0.04M 0.06M 0.06M 0.04M 0.02M
Total liab 4.89M 5.77M 4.97M 4.97M 2.64M
Total stockholder equity 1.19M 4.33M 0.98M 0.98M -1.50957M
Deferred long term liab - - - - 0.27M
Other current liab 2.43M 4.97M 4.35M 4.35M 0.68M
Common stock 26.40M 33.64M 17.13M 17.13M 9.15M
Capital stock 26.40M 24.17M 17.13M 17.13M 9.15M
Retained earnings -27.87715M -33.43966M -18.76806M -18.76806M -13.84995M
Other liab - - - - -
Good will - - - -0.00087M -
Other assets - - - 0.02M 0.29M
Cash 3.92M 9.15M 5.43M 5.43M 0.18M
Cash and equivalents - - - - -
Total current liabilities 4.89M 5.75M 4.97M 4.97M 2.64M
Current deferred revenue - - - - -
Net debt -2.14399M -9.07677M -5.42774M -5.42774M -0.12337M
Short term debt 1.78M 0.05M - - 0.05M
Short long term debt 1.76M - - - -
Short long term debt total 1.78M 0.07M - - 0.05M
Other stockholder equity 2.69M 4.15M 2.64M 2.64M 2.54M
Property plant equipment - - - - 0.07M
Total current assets 5.95M 9.87M 5.79M 5.79M 0.59M
Long term investments - - - - -
Net tangible assets - - - - -1.68737M
Short term investments 1.66M 0.40M 0.09M 0.09M 0.26M
Net receivables 0.32M 0.25M 0.24M 0.24M 0.13M
Long term debt - - - - -
Inventory - - -0.01569M -0.04074M -
Accounts payable 0.68M 0.73M 0.62M 0.62M 1.91M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.02125M -0.02958M -0.02125M -0.02125M 0.64M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.02M 0.01000M 0.04M -0.00704M 0.29M
Deferred long term asset charges - - - - -
Non current assets total 0.14M 0.23M 0.16M 0.16M 0.53M
Capital lease obligations 0.02M 0.05M 0.00000M 0.00000M 0.05M
Long term debt total - - - - -
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-12-31 2022-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-12-31 2022-10-31
Investments -0.52852M -0.23810M -0.02623M -0.00759M -0.00759M
Change to liabilities - - - 1.25M 1.25M
Total cashflows from investing activities -0.54197M -0.33143M -0.02623M -0.00759M -0.00755M
Net borrowings 2.21M -0.04259M -0.04092M -0.07703M -0.07703M
Total cash from financing activities 2.62M 8.71M 11.66M 0.70M 0.69M
Change to operating activities - - - 0.41M 0.41M
Net income -3.85663M -7.31451M -8.62084M -9.41081M -9.35844M
Change in cash -2.65051M 1.60M 5.30M -4.42367M -4.39906M
Begin period cash flow 6.57M 7.56M 0.13M 4.60M 4.57M
End period cash flow 3.92M 9.15M 5.43M 0.18M 0.17M
Total cash from operating activities -4.73406M -6.76325M -6.30147M -5.08356M -5.05528M
Issuance of capital stock 0.00000M 2.19M 11.12M 0.80M 0.80M
Depreciation 0.05M 0.07M 0.06M 0.11M 0.11M
Other cashflows from investing activities -0.01350M 0.05M -0.02623M - -0.00758M
Dividends paid - - - 0.00000M 0.00000M
Change to inventory - - 0.15M - -0.02721M
Change to account receivables 0.02M 0.09M -0.15462M 0.03M 0.03M
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.58M 5.71M 0.59M -0.01970M 0.12M
Change to netincome - - - 2.53M 2.53M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00759M 0.00755M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.03957M -0.18111M -0.96903M 1.69M 1.68M
Stock based compensation 0.81M 1.39M 0.37M 1.65M 1.64M
Other non cash items -1.76348M -0.87382M 3.21M 0.84M 0.83M
Free cash flow -4.73406M -6.76325M -6.30147M -5.09115M -5.06283M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CMND
Clearmind Medicine Inc. Common Shares		 1.07 36.77% 3.98 - - - 0.33 -0.7912
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post-traumatic stress disorder and other health conditions; Polyrizon Ltd. to develop novel intranasal MEAI formulation; and NeuroThera Labs Inc. to develop a therapy for weight loss and Metabolic Dysfunction-Associated Steatotic Liver Disease. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Clearmind Medicine Inc. Common Shares

1220 West 6th Avenue, Vancouver, BC, Canada, V6H 1A5

Key Executives

Name Title Year Born
Dr. Adi Zuloff-Shani Ph.D. Chief Exec. Officer 1970
Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA CFO & Director 1952
Prof. Mark Haden VP of Bus. Devel. 1954
Mr. Gilad Babchuk Head of Strategy & Communication NA
Dr. Adi Zuloff-Shani Ph.D. Chief Executive Officer 1969
Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., C.P.A. Chief Financial Officer 1952
Prof. Mark Haden Vice President of Business Development 1955
Dr. Adi Zuloff-Shani Ph.D. Chief Executive Officer 1967
Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., CPA Chief Financial Officer 1952
Prof. Mark Haden M.S.W. Vice President of Business Development 1953

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions